551.71
0.19%
+1.07
Dopo l'orario di chiusura:
553.00
1.29
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NFLX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$550.64
Aprire:
$547.84
Volume 24 ore:
3.40M
Capitalizzazione di mercato:
$237.73B
Reddito:
$34.93B
Utile/perdita netta:
$6.44B
Rapporto P/E:
55.06
EPS:
10.02
Flusso di cassa netto:
$6.95B
1 W Prestazione:
-0.61%
1M Prestazione:
-10.19%
6M Prestazione:
+31.30%
1 anno Prestazione:
+70.22%
Netflix Inc. Stock (NFLX) Company Profile
Nome
Netflix Inc.
Settore
Industria
Telefono
408-540-3700
Indirizzo
100 Winchester Circle, Los Gatos
Netflix Inc. Stock (NFLX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-01-30 | Downgrade | Seaport Research Partners | Buy → Neutral |
2024-01-25 | Aggiornamento | DZ Bank | Hold → Buy |
2024-01-24 | Reiterato | BMO Capital Markets | Outperform |
2024-01-24 | Reiterato | BofA Securities | Buy |
2024-01-24 | Reiterato | Canaccord Genuity | Buy |
2024-01-24 | Reiterato | Evercore ISI | Outperform |
2024-01-24 | Reiterato | Goldman | Neutral |
2024-01-24 | Reiterato | Guggenheim | Buy |
2024-01-24 | Reiterato | JP Morgan | Overweight |
2024-01-24 | Reiterato | KeyBanc Capital Markets | Overweight |
2024-01-24 | Aggiornamento | Macquarie | Neutral → Outperform |
2024-01-24 | Reiterato | Morgan Stanley | Overweight |
2024-01-24 | Reiterato | Oppenheimer | Outperform |
2024-01-24 | Reiterato | Piper Sandler | Neutral |
2024-01-24 | Reiterato | Pivotal Research Group | Buy |
2024-01-24 | Reiterato | Redburn Atlantic | Buy |
2024-01-24 | Reiterato | Robert W. Baird | Outperform |
2024-01-24 | Reiterato | TD Cowen | Outperform |
2024-01-24 | Reiterato | UBS | Buy |
2024-01-24 | Reiterato | Wells Fargo | Overweight |
2023-09-18 | Reiterato | Evercore ISI | Outperform |
2023-08-25 | Aggiornamento | Loop Capital | Hold → Buy |
2023-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2023-07-17 | Reiterato | Deutsche Bank | Buy |
2023-07-13 | Reiterato | JP Morgan | Overweight |
2023-07-12 | Reiterato | UBS | Buy |
2023-07-05 | Aggiornamento | Goldman | Sell → Neutral |
2023-06-29 | Reiterato | Citigroup | Buy |
2023-06-28 | Reiterato | Oppenheimer | Outperform |
2023-06-13 | Reiterato | BofA Securities | Buy |
2023-06-13 | Reiterato | Guggenheim | Buy |
2023-04-19 | Reiterato | Deutsche Bank | Buy |
2023-04-19 | Reiterato | JP Morgan | Overweight |
2023-04-19 | Reiterato | Jefferies | Buy |
2023-04-19 | Reiterato | Piper Sandler | Neutral |
2023-04-19 | Reiterato | Pivotal Research Group | Buy |
2023-04-19 | Reiterato | Rosenblatt | Neutral |
2023-04-19 | Aggiornamento | UBS | Neutral → Buy |
2023-04-11 | Ripresa | Robert W. Baird | Neutral |
2023-01-23 | Reiterato | Argus | Buy |
2023-01-20 | Reiterato | Canaccord Genuity | Buy |
2023-01-20 | Reiterato | Deutsche Bank | Buy |
2023-01-20 | Reiterato | Evercore ISI | Outperform |
2023-01-20 | Reiterato | Goldman | Sell |
2023-01-20 | Reiterato | Guggenheim | Buy |
2023-01-20 | Reiterato | Jefferies | Buy |
2023-01-20 | Reiterato | MoffettNathanson | Market Perform |
2023-01-20 | Reiterato | Oppenheimer | Outperform |
2023-01-20 | Reiterato | Piper Sandler | Neutral |
2023-01-20 | Reiterato | Pivotal Research Group | Buy |
2023-01-20 | Reiterato | Robert W. Baird | Neutral |
2023-01-20 | Reiterato | The Benchmark Company | Sell |
2023-01-20 | Reiterato | Wedbush | Outperform |
2023-01-20 | Reiterato | Wolfe Research | Outperform |
2023-01-12 | Aggiornamento | Jefferies | Hold → Buy |
2023-01-04 | Iniziato | New Street | Neutral |
2022-12-29 | Aggiornamento | CFRA | Sell → Buy |
2022-12-14 | Reiterato | Jefferies | Hold |
2022-12-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2022-06-14 | Downgrade | The Benchmark Company | Hold → Sell |
2022-06-10 | Downgrade | Goldman | Neutral → Sell |
2022-05-16 | Aggiornamento | Wedbush | Neutral → Outperform |
2022-04-21 | Downgrade | DZ Bank | Buy → Hold |
2022-04-21 | Downgrade | Edward Jones | Buy → Hold |
2022-04-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
2022-04-20 | Downgrade | BofA Securities | Buy → Underperform |
2022-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
2022-04-20 | Aggiornamento | Needham | Underperform → Hold |
2022-04-20 | Downgrade | Oppenheimer | Outperform → Perform |
2022-04-20 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-04-20 | Downgrade | Pivotal Research Group | Buy → Sell |
2022-04-20 | Downgrade | Stifel | Buy → Hold |
2022-04-20 | Downgrade | UBS | Buy → Neutral |
2022-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-04-19 | Iniziato | Rosenblatt | Neutral |
2022-03-09 | Aggiornamento | Wedbush | Underperform → Neutral |
2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
2022-01-31 | Aggiornamento | Edward Jones | Hold → Buy |
2022-01-24 | Downgrade | Jefferies | Buy → Hold |
2022-01-21 | Reiterato | BMO Capital Markets | Outperform |
2022-01-21 | Reiterato | BofA Securities | Buy |
2022-01-21 | Reiterato | Canaccord Genuity | Buy |
2022-01-21 | Reiterato | Cowen | Outperform |
2022-01-21 | Reiterato | Deutsche Bank | Hold |
2022-01-21 | Reiterato | Goldman | Neutral |
2022-01-21 | Reiterato | Guggenheim | Buy |
2022-01-21 | Reiterato | JP Morgan | Overweight |
2022-01-21 | Reiterato | MoffettNathanson | Neutral |
2022-01-21 | Downgrade | Monness Crespi & Hardt | Buy → Neutral |
2022-01-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-01-21 | Reiterato | Oppenheimer | Outperform |
2022-01-21 | Reiterato | Piper Sandler | Overweight |
2022-01-21 | Reiterato | Pivotal Research Group | Buy |
2022-01-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
2022-01-21 | Reiterato | Stifel | Buy |
2022-01-21 | Aggiornamento | The Benchmark Company | Sell → Hold |
2022-01-21 | Downgrade | Truist | Buy → Hold |
2022-01-21 | Reiterato | UBS | Buy |
2022-01-21 | Reiterato | Wolfe Research | Outperform |
2021-12-15 | Reiterato | The Benchmark Company | Sell |
2021-10-20 | Downgrade | Deutsche Bank | Buy → Hold |
2021-10-20 | Reiterato | Monness Crespi & Hardt | Buy |
2021-09-29 | Reiterato | The Benchmark Company | Sell |
2021-09-13 | Iniziato | Goldman | Neutral |
2021-09-08 | Reiterato | JP Morgan | Overweight |
2021-09-07 | Reiterato | Atlantic Equities | Overweight |
2021-07-21 | Reiterato | Credit Suisse | Outperform |
2021-07-21 | Reiterato | Deutsche Bank | Buy |
2021-07-21 | Reiterato | JP Morgan | Overweight |
2021-07-21 | Reiterato | KeyBanc Capital Markets | Overweight |
2021-07-21 | Reiterato | Stifel | Buy |
2021-06-25 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2021-06-25 | Iniziato | Edward Jones | Hold |
2021-05-19 | Ripresa | Jefferies | Buy |
2021-04-21 | Ripresa | Oppenheimer | Outperform |
2021-04-21 | Reiterato | Pivotal Research Group | Buy |
2021-04-21 | Aggiornamento | Stifel | Hold → Buy |
2021-04-06 | Ripresa | Evercore ISI | Outperform |
2021-04-01 | Iniziato | Piper Sandler | Overweight |
2021-03-25 | Reiterato | The Benchmark Company | Sell |
2021-03-23 | Aggiornamento | Argus | Hold → Buy |
2021-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
2021-01-20 | Reiterato | Monness Crespi & Hardt | Buy |
2021-01-20 | Reiterato | Pivotal Research Group | Buy |
2021-01-20 | Reiterato | The Benchmark Company | Sell |
2021-01-20 | Aggiornamento | UBS | Neutral → Buy |
2021-01-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2020-10-21 | Reiterato | BMO Capital Markets | Outperform |
2020-10-21 | Reiterato | Bernstein | Outperform |
2020-10-21 | Reiterato | Jefferies | Buy |
2020-10-21 | Reiterato | Morgan Stanley | Overweight |
2020-10-21 | Reiterato | Oppenheimer | Outperform |
2020-10-21 | Reiterato | Piper Sandler | Overweight |
2020-10-21 | Reiterato | Pivotal Research Group | Buy |
2020-10-21 | Reiterato | RBC Capital Mkts | Outperform |
2020-10-21 | Reiterato | The Benchmark Company | Sell |
2020-10-21 | Reiterato | Wedbush | Underperform |
2020-10-21 | Reiterato | Wells Fargo | Equal Weight |
2020-10-16 | Reiterato | Morgan Stanley | Overweight |
2020-10-15 | Reiterato | Canaccord Genuity | Buy |
2020-10-14 | Reiterato | Goldman | Buy |
2020-10-07 | Reiterato | Pivotal Research Group | Buy |
2020-09-28 | Reiterato | The Benchmark Company | Sell |
2020-09-15 | Iniziato | KeyBanc Capital Markets | Overweight |
2020-09-09 | Ripresa | Raymond James | Mkt Perform |
2020-09-04 | Reiterato | The Benchmark Company | Sell |
2020-07-29 | Reiterato | Loop Capital | Buy |
Mostra tutto
Netflix Inc. Borsa (NFLX) Ultime notizie
Investments to Help Fight Inflation
The Motley Fool
Why Roku Can't Turn the Corner
The Motley Fool
This Streaming Stock Is in Huge Trouble
The Motley Fool
Pick These 4 Stocks With Superb Interest Coverage Ratio
Zacks Investment Research
GTN or NFLX: Which Is the Better Value Stock Right Now?
Zacks Investment Research
5 Stocks to Buy on a Solid Jump in Consumer Spending
Zacks Investment Research
Netflix Inc. Azioni (NFLX) Dati Finanziari
Netflix Inc. (NFLX) Reddito 2024
NFLX ha riportato un ricavo (TTM) di $34.93 miliardi per il trimestre terminato il 2024-03-31, un +9.47% salita anno su anno.
Netflix Inc. (NFLX) Reddito netto 2024
NFLX l'utile netto (TTM) è stato di $6.44 miliardi per il trimestre terminato il 2024-03-31, un +53.23% aumento anno su anno.
Netflix Inc. (NFLX) Flusso di cassa 2024
NFLX ha registrato un flusso di cassa disponibile (TTM) di $6.95 miliardi per il trimestre conclusosi con 2024-03-31, un +136.77% aumento anno su anno.
Netflix Inc. (NFLX) Utile per azione 2024
L'utile per azione (TTM) di NFLX è stato pari a $14.41 per il trimestre terminato il 2024-03-31, un +54.95% crescita anno su anno.
Netflix Inc. Azioni (NFLX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
HASTINGS REED | Executive Chairman |
Apr 01 '24 |
Option Exercise |
60.77 |
20,566 |
1,249,825 |
20,594 |
HASTINGS REED | Executive Chairman |
Apr 01 '24 |
Sale |
610.42 |
20,566 |
12,553,955 |
28 |
Peters Gregory K | Co-CEO |
Mar 18 '24 |
Option Exercise |
127.49 |
5,352 |
682,326 |
18,442 |
Peters Gregory K | Co-CEO |
Mar 18 '24 |
Sale |
625.00 |
5,352 |
3,345,000 |
13,090 |
HASTINGS REED | Executive Chairman |
Mar 01 '24 |
Option Exercise |
67.59 |
18,494 |
1,249,930 |
18,522 |
HASTINGS REED | Executive Chairman |
Mar 01 '24 |
Sale |
611.22 |
18,494 |
11,303,912 |
28 |
Peters Gregory K | Co-CEO |
Feb 27 '24 |
Option Exercise |
117.22 |
5,821 |
682,338 |
18,911 |
MATHER ANN | Director |
Feb 27 '24 |
Option Exercise |
102.09 |
3,673 |
374,973 |
3,673 |
Peters Gregory K | Co-CEO |
Feb 27 '24 |
Sale |
600.00 |
5,821 |
3,492,600 |
13,090 |
MATHER ANN | Director |
Feb 27 '24 |
Sale |
600.00 |
3,673 |
2,203,800 |
0 |
Capitalizzazione:
|
Volume (24 ore):